{name}
{subtitle}
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
city
~30 mi. (Washington, Illinois, +523 more cities)
facility
Illinois CancerCare - Washington
drug
cabozantinib, +2 more drugs
drug type
immunotherapy, +1 more type
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
city
~30 mi. (Washington, Illinois, +454 more cities)
facility
Illinois CancerCare - Washington
drug
brentuximab vedotin, +7 more drugs
drug type
chemotherapy, +3 more types
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
city
~30 mi. (Washington, Illinois, +233 more cities)
facility
Illinois CancerCare - Washington
drug
degarelix, +4 more drugs
drug type
hormone therapy, +1 more type
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
city
~30 mi. (Eureka, Illinois, +825 more cities)
facility
Illinois CancerCare-Eureka
biomarker
AKT1 Mutation, +91 more biomarkers
condition
Breast Carcinoma, +3 more conditions
drug
adavosertib, +26 more drugs
drug type
immunotherapy, +1 more type
Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
city
~30 mi. (Washington, Illinois, +143 more cities)
facility
Illinois CancerCare - Washington
drug
ixazomib, +1 more drug
drug type
chemotherapy, +1 more type
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
city
~30 mi. (Eureka, Illinois, +327 more cities)
facility
Illinois CancerCare-Eureka
drug
bortezomib, +3 more drugs
drug type
chemotherapy, +3 more types